DLB, Parkinson's Disease, and Alzheimer's Disease: Cross-Disease Comparison Matrix

Migration, Crosslink

📖

DLB, Parkinson's Disease, and Alzheimer's Disease: Cross-Disease Comparison Matrix

active

wiki page Created: 2026-04-02T07:20:11 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-diseases-dementia-lewy-bodies-parki

📖 Wiki Page

disease3237 wordssynced 2026-04-02

DLB, Parkinson's Disease, and Alzheimer's Disease: Cross-Disease Comparison Matrix

Overview

Dementia with Lewy Bodies (DLB), [Parkinson's Disease](/diseases/parkinsons-disease) (PD), and [Alzheimer's Disease](/diseases/alzheimers-disease) (AD) are the three most common neurodegenerative disorders causing cognitive decline in aging populations. While each has a distinct primary pathology, they share substantial clinical, neurochemical, and mechanistic overlap that has critical implications for diagnosis, treatment, and biomarker development.

The comparison below examines these three diseases across eight key dimensions, revealing both their distinct signatures and the shared pathways that offer therapeutic targets applicable across multiple conditions.

Pathological Comparison

Primary Proteinopathies

...

DLB, Parkinson's Disease, and Alzheimer's Disease: Cross-Disease Comparison Matrix

Overview

Dementia with Lewy Bodies (DLB), [Parkinson's Disease](/diseases/parkinsons-disease) (PD), and [Alzheimer's Disease](/diseases/alzheimers-disease) (AD) are the three most common neurodegenerative disorders causing cognitive decline in aging populations. While each has a distinct primary pathology, they share substantial clinical, neurochemical, and mechanistic overlap that has critical implications for diagnosis, treatment, and biomarker development.

The comparison below examines these three diseases across eight key dimensions, revealing both their distinct signatures and the shared pathways that offer therapeutic targets applicable across multiple conditions.

Pathological Comparison

Primary Proteinopathies

| Feature | DLB | Parkinson's Disease | Alzheimer's Disease |
|---------|-----|---------------------|---------------------|
| Primary protein | [Alpha-synuclein](/proteins/alpha-synuclein) | [Alpha-synuclein](/proteins/alpha-synuclein) | [Amyloid-beta](/proteins/amyloid-beta) + [Tau](/proteins/tau) |
| Key inclusions | Cortical Lewy bodies, Lewy neurites | Brainstem Lewy bodies, Lewy neurites | Amyloid plaques, neurofibrillary tangles |
| Inclusion location | Cortex, limbic, brainstem | Substantia nigra, cortex (in PDD) | Hippocampus, cortex |
| Co-pathology rate | ~50-60% have concurrent AD pathology[@donovan2024] | ~40-60% have AD co-pathology[@aarsland2021] | ~20-30% have alpha-synuclein co-pathology |
| Staging pattern | Diffuse cortical early; less brainstem-predominant[@ferman2024] | Braak staging: brainstem → limbic → cortical | Braak NFT stages; amyloid follows separate pattern |

Key Distinction: Alpha-Synuclein vs Tau/Amyloid

DLB: Alpha-synuclein is the primary driver. Cortical involvement is early and prominent. Lewy bodies distributed diffusely across cortex and limbic system simultaneously[@mckeith2024].
PD: Alpha-synuclein follows a brainstem-to-cortical gradient. Motor symptoms precede cortical involvement by years[@aarsland2021].
AD: Distinct dual proteinopathy — amyloid-beta plaques (extracellular) and tau neurofibrillary tangles (intracellular). Amyloid accumulation precedes tau spreading by years.

Co-Pathology and Mixed Dementia

The boundary between these diseases is blurred by frequent co-pathology[@jellinger2023]:

DLB/AD: 50-60% of DLB cases have moderate-to-severe AD co-pathology. The presence of amyloid-beta and tau modifies the clinical phenotype and predicts faster decline.
PD/AD: Many PD patients develop sufficient amyloid and tau pathology to meet criteria for concomitant AD.
PDD vs DLB: The 1-year rule — when motor symptoms precede cognitive decline by >1 year, the diagnosis is PDD; when cognitive and motor symptoms emerge together or cognitive precedes, the diagnosis is DLB. Pathologically, the distinction is subtle.

Neurotransmitter Deficits

Dopaminergic System

| Feature | DLB | Parkinson's Disease | Alzheimer's Disease |
|---------|-----|---------------------|---------------------|
| Nigrostriatal dopamine loss | Moderate (less than PD) | Severe | Mild or absent |
| Motor response to levodopa | Variable; often modest | Good to excellent | Not applicable |
| Dopaminergic cell loss | Substantia nigra pars compacta | Marked, progressive loss | Limited |
| Striatal dopamine depletion | 50-70% | 70-90% | Minimal |

DLB has significant dopaminergic loss in the substantia nigra, causing parkinsonism, but the depletion is generally less severe than in PD[@dupre2024]. This correlates with the often less robust response to levodopa in DLB compared to PD.

Cholinergic System

| Feature | DLB | Parkinson's Disease | Alzheimer's Disease |
|---------|-----|---------------------|---------------------|
| Nucleus basalis of Meynert loss | Severe (80-90%)[@bohnen2023] | Moderate (30-50%) | Moderate (30-50%) |
| Cortical cholinergic denervation | Severe | Moderate | Moderate |
| Cholinesterase inhibitor response | Often robust | Modest | Moderate |
| Pedunculopontine nucleus | Affected (causes RBD, gait dysfunction) | Affected (causes gait dysfunction) | Less affected |

The cholinergic deficit in DLB is the most severe of all neurodegenerative dementias[@bohnen2023]. This explains:

The dramatic response to cholinesterase inhibitors in DLB
The prominent visual hallucinations from cholinergic deafferentation of visual cortex
The profound fluctuations in attention from loss of basal forebrain arousal regulation

Additional Neurotransmitter Systems

| Neurotransmitter | DLB | PD | AD |
|-----------------|-----|----|----|
| Noradrenergic (locus coeruleus) | Severe loss | Moderate loss | Early but less severe |
| Serotonergic (raphe) | Affected | Affected | Affected |
| GABAergic | Affected | Loss of GABAergic interneurons in substantia nigra | Synaptic GABA loss |
| Glutamatergic | Thalamic relay disruption | Cortical glutamate dysregulation | Cortical glutamate excitotoxicity |

The noradrenergic deficit is particularly prominent in DLB, contributing to the characteristic attention fluctuations[@ffytche2024]. The locus coeruleus is affected early by alpha-synuclein pathology in both DLB and PD, but the additional cholinergic loss in DLB creates a unique combination of arousal system failure.

Autonomic Dysfunction

Comparison of Autonomic Failure

| Feature | DLB | Parkinson's Disease | Alzheimer's Disease |
|---------|-----|---------------------|---------------------|
| Overall severity | Early, prominent | Mild-moderate, develops later | Late, less prominent |
| Orthostatic hypotension | Common (40-60%)[@orimo2024] | Common (30-50%) | Uncommon |
| Supine hypertension | Common (baroreflex failure) | Present | Uncommon |
| Constipation | Very common (often predates diagnosis by decades) | Very common | Less common |
| Urinary dysfunction | Common (urgency, retention) | Common | Less common |
| Anhidrosis | Present | Present | Rare |
| Syncope | Common | Occasional | Rare |
| Cardiac sympathetic denervation | Severe (MIBG scan markedly reduced) | Present | Absent or mild |
| Mechanism | Peripheral and central alpha-synuclein | Peripheral and central alpha-synuclein | AD pathology less affects autonomic centers |

DLB and PD share a common autonomic phenotype driven by alpha-synuclein pathology in peripheral postganglionic sympathetic neurons, enteric nervous system, and central autonomic centers[@orimo2024]. The loss of cardiac sympathetic innervation (detected by MIBG scintigraphy or PET imaging of sympathetic nerves) is a particularly useful biomarker distinguishing DLB from AD, and can also help differentiate PD from other parkinsonisms.

Postganglionic Sympathetic Imaging

| Modality | DLB | PD | AD |
|----------|-----|----|----|
| MIBG myocardial scintigraphy | Markedly reduced uptake | Reduced uptake | Normal or near-normal |
| 6-[18F]fluorodopamine PET | Reduced | Reduced | Normal |
| Cardiac sympathetic density | Severely reduced | Reduced | Preserved |

This makes cardiac autonomic imaging a key tool in the differential diagnosis between DLB and AD, and between Lewy body diseases and other dementias.

Cognitive Trajectory

Cognitive Profile Comparison

| Domain | DLB | Parkinson's Disease | Alzheimer's Disease |
|--------|-----|---------------------|---------------------|
| Onset pattern | Attention/executive deficits first | Executive dysfunction early; motor precedes | Memory encoding deficit first |
| Fluctuating cognition | Core feature — early, prominent | Can occur, less prominent | Absent |
| Visuospatial deficits | Early, prominent | Present but secondary | Variable, later |
| Memory | Retrieval > encoding deficit; preserved recognition | Working memory, executive | Encoding deficit; recognition impaired |
| Language | Relatively preserved early | Mild anomia | Progressive anomia |
| Attention | Severe, labile fluctuations | Impaired but more stable | Impaired but stable |

Cognitive Decline Trajectory

| Feature | DLB | PD | AD |
|---------|-----|----|----|
| Rate of decline | Rapid (median 4-6 years from diagnosis) | Moderate (faster if PDD develops) | Slow-moderate (8-10 years average) |
| Dementia timeline | Cognitive onset simultaneous with or preceding motor | Develops in up to 80% of long-term PD patients | Progressive from memory onset |
| Plateau periods | Uncommon; progressive | Can have plateaus with treatment | Possible brief plateaus |
| End-stage | Severe global impairment, parkinsonism, falls | Severe motor + cognitive | Severe memory, language, behavioral |

DLB-Specific Cognitive Features

The fluctuating cognition in DLB is a cardinal feature driven by the combined loss of cholinergic (nucleus basalis) and noradrenergic (locus coeruleus) inputs to the thalamocortical arousal system[@dupre2024]. This creates moments of near-normal cognition alternating with profound confusion — a phenomenon not seen in AD.

Visual hallucinations in DLB are typically:

Well-formed, detailed, and vivid (seeing people, animals)
Often occur early and persist throughout the disease course
Accompanied by relatively preserved insight early on
Distinct from the less-formed, less-frequent hallucinations of AD

Treatment Overlap

Pharmacological Comparison

| Treatment | DLB | Parkinson's Disease | Alzheimer's Disease |
|-----------|-----|---------------------|---------------------|
| Cholinesterase inhibitors | First-line; often robust response[@bohnen2023] | Modest benefit | First-line; moderate response |
| Memantine | Second-line; used off-label | Not standard | Used in moderate-severe disease |
| Levodopa/Carbidopa | Variable; modest benefit; can worsen hallucinations | First-line; robust benefit | Not applicable |
| Dopamine agonists | Use cautiously; can worsen psychosis | First-line; effective but side effects | Not applicable |
| MAO-B inhibitors | Limited role | First-line adjunct | Not applicable |
| Antipsychotics | AVOID — severe sensitivity, can be fatal | Use cautiously; need PD-specific agents | Use for severe psychosis |
| Pimavanserin | Used off-label for psychosis | FDA-approved for PD psychosis | Not approved |
| RBD treatments | Melatonin, clonazepam | Melatonin, clonazepam | Not typically relevant |

Key Treatment Differences

Levodopa is the cornerstone of PD treatment but has limited efficacy in DLB for several reasons:

The dopaminergic loss in DLB is less severe than in PD
The cognitive and autonomic symptoms of DLB do not respond to dopaminergic therapy
High doses of dopaminergic drugs can worsen hallucinations and psychosis in DLB

Cholinesterase inhibitors show the greatest efficacy in DLB among all dementias, with rivastigmine having the most robust evidence base. The severe cholinergic deficit in DLB (80-90% loss in the nucleus basalis of Meynert) creates a strong therapeutic rationale.

Antipsychotic Sensitivity

DLB patients have a profound sensitivity to typical antipsychotics (haloperidol, risperidone, etc.) that can cause:

Life-threatening parkinsonism
Neuroleptic malignant syndrome
Rapid cognitive decline
Increased mortality

Even atypical antipsychotics carry elevated risk in DLB. Pimavanserin (5-HT2A inverse agonist) is the preferred agent for DLB psychosis as it has no D2 receptor activity and carries lower extrapyramidal risk.

Deep Brain Stimulation

| Target | DLB | PD | AD |
|--------|-----|----|----|
| Subthalamic nucleus | Not standard | First-line for motor symptoms | Not applicable |
| Globus pallidus interna | Not standard | Used for dyskinesias | Not applicable |
| Nucleus basalis of Meynert | Experimental target for cognition | Investigational | Investigational |
| Pedunculopontine nucleus | Investigational (for RBD/gait) | Investigational | Not applicable |

Biomarker Overlap

Fluid Biomarkers

| Biomarker | DLB | PD | AD | Interpretation |
|-----------|-----|----|----|---------------|
| CSF alpha-synuclein (total) | Reduced | Reduced | Normal | Reflects neuronal loss; not disease-specific |
| CSF alpha-synuclein (phosphorylated, pSer129) | Elevated | Elevated | Normal | Indicates alpha-synuclein pathology |
| RT-QuIC/PMCA seed amplification | ~90% sensitivity/specificity | Positive in majority | Negative | Detects misfolded alpha-synuclein |
| CSF amyloid-beta 42 | Reduced in ~50% (co-pathology) | Normal or reduced | Reduced | Amyloid deposition |
| CSF total tau | Mildly elevated | Normal | Elevated | Neurodegeneration |
| CSF phosphorylated tau (p-tau181, p-tau217) | Mildly elevated (co-pathology) | Normal | Elevated | Tau pathology |
| Neurofilament light chain (NfL) | Elevated | Elevated (less than DLB) | Elevated | General neurodegeneration; DLB > PD > AD |
| Neurogranin | Elevated | Slightly elevated | Elevated | Synaptic dysfunction |
| YKL-40 (neuroinflammation) | Elevated | Elevated | Elevated | Microglial activation |

Imaging Biomarkers

| Modality | DLB | PD | AD |
|---------|-----|----|----|
| Dopaminergic SPECT/PET (DaTscan) | Reduced striatal binding | Reduced striatal binding | Normal |
| FDG-PET | Posterior cingulate, occipital hypometabolism | Frontal/striatal hypometabolism | Posterior cingulate, medial temporal |
| Amyloid PET (Florbetapir/Flutemetamol) | Positive in ~50% (co-pathology) | Variable | Positive in ~90% |
| Tau PET (Flortaucipir) | Focal uptake in basal ganglia; less than AD | Limited basal ganglia uptake | High cortical uptake, temporal > frontal |
| Structural MRI | Less atrophy than AD; relative preservation of medial temporal | Putaminal iron deposition | Hippocampal and entorhinal atrophy |
| MIBG cardiac scan | Markedly reduced | Reduced | Normal |
| Diffusion MRI | Putaminal diffusion changes | Less prominent | Different pattern |
| MR spectroscopy | Reduced occipital NAA | Variable | Reduced NAA in temporal cortex |

Biomarker Overlap and Cross-Disease Patterns

Alpha-synuclein markers (CSF total/phosphorylated, RT-QuIC, skin biopsy, MIBG) are shared between DLB and PD and do not distinguish between them. They distinguish both from AD.

Amyloid markers (CSF Aβ42, amyloid PET) are shared between AD and DLB (with co-pathology). They distinguish AD from PD and help identify the DLB/AD mixed phenotype.

Tau markers (CSF p-tau, tau PET) are shared between AD and DLB (with co-pathology). They are largely normal in pure PD.

Neurodegeneration markers (NfL, total tau) are elevated across all three diseases, with the highest levels typically in DLB, reflecting the combination of multiple pathologies.

Biomarker-Based Differential Diagnosis Algorithm

Patient with cognitive decline and/or parkinsonism:
↓
Dopaminergic imaging (DaTscan)?
↓
Reduced → Lewy body disease (DLB or PD)
↓
Amyloid PET / CSF Aβ42?
↓
Positive → DLB + AD co-pathology (mixed dementia)
Negative → DLB (pure) or PD (if motor-first)
↓
Cognitive onset relative to motor symptoms?
↓
Motor first (>1 year) → Parkinson's Disease Dementia
Cognitive simultaneous or first → Dementia with Lewy Bodies

Genetic Overlap

| Gene | DLB | Parkinson's Disease | Alzheimer's Disease |
|------|-----|---------------------|---------------------|
| [SNCA](/genes/snca) (multiplications, point mutations) | Risk factor; A53T causes familial DLB/PD | Major cause of familial PD | Not a direct risk factor |
| [GBA](/genes/gba) (mutations) | Major risk factor; 5-10x increased risk | Major risk factor; 5-10x increased risk | Not a direct risk factor |
| [LRRK2](/genes/lrrk2) (G2019S) | Can cause DLB phenotype[@walker2024] | Most common cause of familial PD | Not a direct risk factor |
| [APOE](/genes/apoe) (ε4 allele) | Modest risk factor | Modest risk factor | Major risk factor (3-4x heterozygote, 10-15x homozygote) |
| [TREM2](/genes/trem2) (risk variants) | Modest effect | Modest effect | 3-fold increased risk |
| SNCAA53T transgenic | Causes familial synucleinopathy | Causes familial PD | Not applicable |

GBA mutations are the strongest genetic link between DLB and PD. The same mutations that increase PD risk by 5-10 fold also increase DLB risk by a similar magnitude, and GBA-associated cases of both diseases share clinical features: earlier onset, faster progression, more prominent cognitive fluctuations.

APOE ε4 has a more modest effect on DLB risk than on AD risk, but the presence of APOE ε4 in DLB increases the likelihood of AD co-pathology and faster decline.

Mechanistic Convergence and Divergence

Mermaid diagram (expand to render)

Convergence Points

Synaptic failure — All three diseases ultimately converge on synaptic loss as a central mechanism of cognitive decline. Alpha-synuclein oligomers, amyloid-beta, and tau all directly impair synaptic function through different mechanisms.

Neuroinflammation — Microglial activation and chronic neuroinflammation are shared features across all three diseases, creating a potential common therapeutic target.

Protein homeostasis failure — Impaired autophagy-lysosomal and ubiquitin-proteasome systems contribute to protein aggregation in all three conditions. GBA mutations (lysosomal glucocerebrosidase) link DLB and PD through this pathway.

Mitochondrial dysfunction — Oxidative stress and mitochondrial deficits are shared across all three diseases, with PD having the most prominent complex I dysfunction.

Divergence Points

Primary initiating protein — AD (amyloid-beta/tau) vs DLB/PD (alpha-synuclein)

Regional vulnerability — Substantia nigra (PD) vs nucleus basalis (DLB) vs hippocampus (AD)

Neurotransmitter profile — Dopamine loss dominant in PD; acetylcholine loss dominant in DLB; glutamate dysregulation more prominent in AD

Cross-Disease Therapeutic Implications

Shared Drug Targets

| Target | DLB | PD | AD |
|--------|-----|----|----|
| Alpha-synuclein aggregation | Primary | Primary | Potential (co-pathology) |
| Neuroinflammation | Target | Target | Target |
| Autophagy enhancement | Target | Target | Target |
| Neurotrophic support | Target | Target | Target |
| Synaptic protection | Target | Target | Target |
| Mitochondrial support | Target | Target | Target |

Cross-Disease Drug Candidates

Ambroxol: Glucocerebrosidase chaperone; in trials for PD and DLB (GBA-related)
Nilotinib: BCR-ABL inhibitor; lowers alpha-synuclein; in trials for PD
Anle138b: Alpha-synuclein oligomer modulator; PD/DLB trials
Masitinib: Tyrosine kinase inhibitor; neuroinflammation; AD/PD trials
Blarcamesine: MAPK inhibitor; neurotrophic; AD/PD trials

Summary Matrix

| Dimension | DLB | Parkinson's Disease | Alzheimer's Disease |
|-----------|-----|---------------------|---------------------|
| Primary protein | Alpha-synuclein | Alpha-synuclein | Amyloid-beta + Tau |
| Key pathology | Cortical Lewy bodies | Brainstem Lewy bodies | Plaques + NFTs |
| First symptom | Cognitive/behavioral | Motor (tremor, bradykinesia) | Memory |
| Cholinergic loss | Severe (80-90%) | Moderate | Moderate |
| Dopaminergic loss | Moderate | Severe | Minimal |
| Autonomic dysfunction | Early, severe | Moderate, progressive | Late, mild |
| Visual hallucinations | Early, core feature | Late (drug-induced) | Late, less formed |
| Fluctuating cognition | Prominent | Mild | Absent |
| Levodopa response | Variable | Good-excellent | N/A |
| Cholinesterase response | Robust | Modest | Moderate |
| Disease duration | 4-8 years | 10-20 years | 8-12 years |
| Co-pathology | AD in 50-60% | AD in 40-60% | Alpha-syn in 20-30% |

Cross-Reference Links

[Dementia with Lewy Bodies](/diseases/dementia-lewy-bodies) — DLB full page
[Parkinson's Disease](/diseases/parkinsons-disease) — PD full page
[Alzheimer's Disease](/diseases/alzheimers-disease) — AD full page
[Parkinson's Disease Dementia](/diseases/parkinsons-disease-dementia) — PDD (DLB/PD overlap)
[Alpha-Synucleinopathies Comparison](/diseases/alpha-synucleinopathies-comparison) — DLB, PD, MSA, PSP matrix
[Alzheimer's vs Parkinson's Comparison](/diseases/alzheimers-parkinsons-comparison) — AD/PD bilateral comparison
[DLB Biomarkers](/biomarkers/dementia-lewy-bodies-biomarkers) — DLB-specific biomarker page
[Parkinson's Disease Biomarkers](/biomarkers/parkinsons-disease-biomarkers) — PD biomarker page

References

McKeith IG, et al. Diagnosis and management of dementia with Lewy bodies: fifth consensus report (2024)

Jellinger KA. DLB and PDD: similarities and differences (2023)

Bohnen NI, et al. Cholinergic deficit in DLB: a key target for therapy (2023)

Ferman TJ, et al. Alpha-synuclein staging patterns in DLB (2024)

Orimo A, et al. Mechanisms of autonomic dysfunction in DLB (2024)

Walker Z, et al. LRRK2 G2019S mutations and DLB (2024)

Aarsland D, et al. Parkinson disease-associated cognitive impairment (2021)

Zaccai J, et al. Epidemiology of DLB: systematic review (2023)

Donovan NJ, et al. AD neuropathology in DLB: systematic review (2024)

Blauwendraat C, et al. The genetic architecture of Parkinson's disease (2020)

Dupré E, et al. Neurotransmitter deficits in AD and Lewy body diseases (2024)

Ffytche DH, et al. Visual hallucinations in Lewy body disease: a multimodal perspective (2024)

Sims JR, et al. Donanemab in early Alzheimer's disease (2023)

Cullen NC, et al. Blood biomarkers for Alzheimer's disease (2024)

Kantarci K, et al. CSF biomarkers in DLB: comparison with AD and PD (2023)

slug	diseases-dementia-lewy-bodies-parkinsons-alzheimers-comparison
kg_node_id	None
entity_type	disease
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-a83e6397006c
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'diseases-dementia-lewy-bodies-parkinsons-alzheimers-comparison'}
_schema_version	1

📗 Cite This Artifact

DLB, Parkinson's Disease, and Alzheimer's Disease: Cross-Disease Comparison Matrix

DLB, Parkinson's Disease, and Alzheimer's Disease: Cross-Disease Comparison Matrix

Overview

Pathological Comparison

Primary Proteinopathies

DLB, Parkinson's Disease, and Alzheimer's Disease: Cross-Disease Comparison Matrix

Overview

Pathological Comparison

Primary Proteinopathies

Key Distinction: Alpha-Synuclein vs Tau/Amyloid

Co-Pathology and Mixed Dementia

Neurotransmitter Deficits

Dopaminergic System

Cholinergic System

Additional Neurotransmitter Systems

Autonomic Dysfunction

Comparison of Autonomic Failure

Postganglionic Sympathetic Imaging

Cognitive Trajectory

Cognitive Profile Comparison

Cognitive Decline Trajectory

DLB-Specific Cognitive Features

Treatment Overlap

Pharmacological Comparison

Key Treatment Differences

Antipsychotic Sensitivity

Deep Brain Stimulation

Biomarker Overlap

Fluid Biomarkers

Imaging Biomarkers

Biomarker Overlap and Cross-Disease Patterns

Biomarker-Based Differential Diagnosis Algorithm

Genetic Overlap

Mechanistic Convergence and Divergence

Convergence Points

Divergence Points

Cross-Disease Therapeutic Implications

Shared Drug Targets

Cross-Disease Drug Candidates

Summary Matrix

Cross-Reference Links

References

See Also

💬 Discussion